BGI Genomics Co., Ltd. (300676.SZ)
CNY 49.18
(-0.06%)
CNY 49.18
(-0.06%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.17 Billion CNY | -41.08% |
| 2022 | 3.68 Billion CNY | -6.15% |
| 2021 | 3.93 Billion CNY | -22.07% |
| 2020 | 5.04 Billion CNY | 236.31% |
| 2019 | 1.49 Billion CNY | 6.84% |
| 2018 | 1.4 Billion CNY | 17.64% |
| 2017 | 1.19 Billion CNY | 19.3% |
| 2016 | 1 Billion CNY | 36.55% |
| 2015 | 732.5 Million CNY | 40.91% |
| 2014 | 519.84 Million CNY | -10.99% |
| 2013 | 584.03 Million CNY | 53.9% |
| 2012 | 379.48 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 430.11 Million CNY | 7.39% |
| 2024 Q3 | 393.85 Million CNY | -8.43% |
| 2024 Q1 | 400.53 Million CNY | -38.92% |
| 2023 Q3 | 566.55 Million CNY | 8.66% |
| 2023 FY | 2.17 Billion CNY | -41.08% |
| 2023 Q1 | 430.01 Million CNY | -64.52% |
| 2023 Q2 | 521.4 Million CNY | 21.25% |
| 2023 Q4 | 655.73 Million CNY | 15.74% |
| 2022 FY | 3.68 Billion CNY | -6.15% |
| 2022 Q4 | 1.21 Billion CNY | 57.94% |
| 2022 Q3 | 767.31 Million CNY | -12.12% |
| 2022 Q2 | 873.18 Million CNY | 4.37% |
| 2022 Q1 | 836.59 Million CNY | -2.96% |
| 2021 Q2 | 1.23 Billion CNY | 24.11% |
| 2021 Q4 | 862.08 Million CNY | 2.43% |
| 2021 FY | 3.93 Billion CNY | -22.07% |
| 2021 Q3 | 841.64 Million CNY | -31.75% |
| 2021 Q1 | 993.71 Million CNY | 45.81% |
| 2020 FY | 5.04 Billion CNY | 236.31% |
| 2020 Q1 | 444.03 Million CNY | 27.9% |
| 2020 Q2 | 2.24 Billion CNY | 404.49% |
| 2020 Q3 | 1.67 Billion CNY | -25.07% |
| 2020 Q4 | 681.52 Million CNY | -59.4% |
| 2019 Q4 | 347.16 Million CNY | -14.45% |
| 2019 FY | 1.49 Billion CNY | 6.84% |
| 2019 Q3 | 405.78 Million CNY | -0.69% |
| 2019 Q2 | 408.6 Million CNY | 20.78% |
| 2019 Q1 | 338.3 Million CNY | -14.75% |
| 2018 FY | 1.4 Billion CNY | 17.64% |
| 2018 Q1 | 277.16 Million CNY | -17.09% |
| 2018 Q2 | 345.11 Million CNY | 24.52% |
| 2018 Q3 | 384.71 Million CNY | 11.47% |
| 2018 Q4 | 396.84 Million CNY | 3.15% |
| 2017 Q1 | 237.52 Million CNY | -4.78% |
| 2017 Q2 | 309.08 Million CNY | 30.13% |
| 2017 Q3 | 312.44 Million CNY | 1.09% |
| 2017 Q4 | 334.28 Million CNY | 6.99% |
| 2017 FY | 1.19 Billion CNY | 19.3% |
| 2016 FY | 1 Billion CNY | 36.55% |
| 2016 Q4 | 249.45 Million CNY | -17.25% |
| 2016 Q3 | 301.45 Million CNY | 9.43% |
| 2016 Q2 | 275.47 Million CNY | 58.43% |
| 2016 Q1 | 173.87 Million CNY | 0.0% |
| 2015 FY | 732.5 Million CNY | 40.91% |
| 2015 Q1 | 142.54 Million CNY | 0.0% |
| 2015 Q2 | 142.54 Million CNY | 0.0% |
| 2014 FY | 519.84 Million CNY | -10.99% |
| 2013 FY | 584.03 Million CNY | 53.9% |
| 2012 FY | 379.48 Million CNY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 4.15 Billion CNY | 47.723% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.72 Billion CNY | 20.27% |
| Dirui Industrial Co.,Ltd. | 669.29 Million CNY | -224.31% |
| Beijing Strong Biotechnologies, Inc. | 1.3 Billion CNY | -66.923% |
| Medicalsystem Biotechnology Co., Ltd. | 834.37 Million CNY | -160.147% |
| Maccura Biotechnology Co.Ltd | 1.51 Billion CNY | -43.6% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.72 Billion CNY | -25.867% |
| Guangdong Hybribio Biotech Co.,Ltd. | 662.35 Million CNY | -227.712% |
| Amoy Diagnostics Co., Ltd. | 871.54 Million CNY | -149.054% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 329.31 Million CNY | -559.129% |